Skip to main content
SpringerLink
Log in

Lessons Learned from Prevention Programs: Different Endpoints Should Be Used in Secondary and Tertiary Prevention

  • Chapter
  • First Online:
Clinical Cancer Prevention

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 188))

Abstract

It is mandatory to compare cost and consequences of healthcare services if public support is requested. This request will apply to all healthcare services including prevention. As the demand for health care will always exceed the available resources, methods that make it possible to select the “best” programs for implementation have to be developed. The selection of the “best” programs is not easy because there exist so far no generally accepted quality criteria that can be used to identify the “best” prevention programs.

Based on a model on structural and functional properties of a disease, it is concluded that the traditional outcomes of treatment and prevention may be useful for the evaluation of tertiary prevention programs, but not of secondary prevention programs. Neither the traditional endpoints of treatment studies nor traditional surrogate parameters are useful for the evaluation of secondary prevention programs.

Using the assumptions of the model and a list of available data in secondary prevention programs we recommend to assess five indicators for description of the value of a secondary prevention program: quality of life, surrogates for life expectancy, the perspective of the assessor, the conditions of assessment, and finally the payment. As each of these five items offers two possible values prevention programs may be classified into 32 different groups.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • USPSTF. http://www.breastcancer.org/symptoms/testing/new_research

  • Adams LS, Chen S (2009) Phytochemicals for breast cancer prevention by targeting aromatase. Front Biosci 14:3846–3863

    Article  PubMed  Google Scholar 

  • Agrawal A, Fentiman IS (2008) NSAIDs and breast cancer: a possible prevention and treatment strategy. Int J Clin Pract 62:444–449

    Article  PubMed  CAS  Google Scholar 

  • Baselga J, Senn H-J (2008) The perspective and role of the medical oncologist in cancer prevention: a position paper by the European Society for Medical Oncology (editorial). Ann Oncol 19: 1033–1035. doi:10.1093/annonc/mdn366

    Article  PubMed  CAS  Google Scholar 

  • Bauer T, Gitt AK, Jünger C, Zahn R, Koeth O, Towae F, Schwarz AK, Bestehorn K, Senges J, Zeymer U; for the Acute Coronary Syndromes Registry (ACOS) investigators (2010 Mar 25). Guideline-recommended secondary prevention drug therapy after acute myocardial infarction: predictors and outcomes of nonadherence. Eur J Cardiovasc Prev Rehabil [Epub ahead of print]

    Google Scholar 

  • Bonanni B, Lazzeroni M (2009) Retinoids and breast cancer prevention. Recent Results Cancer Res 181:77–82

    Article  PubMed  CAS  Google Scholar 

  • Bosch-Capblanch X, Abba K, Prictor M, Garner P (2007) Contracts between patients and healthcare practitioners for improving patients’ adherence to treatment, prevention and health promotion activities. Cochrane Database Syst Rev (2), CD004808

    Google Scholar 

  • Broudy DW, Swint JM, Lairson DR (1979) Prospective economic evaluation of lead poisoning prevention programs. J Community Health 4:291–301

    Article  PubMed  CAS  Google Scholar 

  • Brown B (2008 Nov) Structural and functional imaging of the retina: new ways to diagnose and assess retinal disease. Clin Exp Optom 91(6): 504–14

    Article  PubMed  Google Scholar 

  • Cazzaniga M, Decensi A, Bonanni B, Luini A, Gentilini O (2009) Biomarkers for risk assessment and prevention of breast cancer. Curr Cancer Drug Targets 9:482–499

    Article  PubMed  CAS  Google Scholar 

  • Cummings SR, Tice JA, Bauer S, Browner WS, Cuzick J, Ziv E, Vogel V, Shepherd J, Vachon C, Smith-Bindman R, Kerlikowske K (2009) Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst 101:384–398

    Article  PubMed  Google Scholar 

  • Dalziel K, Segal L (2006) Point: uncertainty in the economic analysis of school-based obesity prevention programs: urgent need for quality evaluation. Obesity 14:1481–1482

    Article  PubMed  Google Scholar 

  • DeKosky ST (2006) Maintaining adherence and retention in dementia prevention trials. Neurology 67(Suppl 3):S14–16

    Article  PubMed  Google Scholar 

  • DiMatteo MR (2003) Future directions in research on consumer-provider communication and adherence to cancer prevention and treatment. Patient Educ Couns 50:23–26

    Article  PubMed  Google Scholar 

  • Ebrahim S (1998) Detection, adherence and control of hypertension for the prevention of stroke: a systematic review. Health Technol Assess 2:1–78

    Google Scholar 

  • Ernst E, Canter PH (2005) Limitations of “pragmatic” trials. Postgrad Med J 81:203

    Article  PubMed  CAS  Google Scholar 

  • Foster EM, Dodge KA, Jones D (2003) Issues in the economic evaluation of prevention programs. Appl Dev Sci 7:76–86

    Article  PubMed  Google Scholar 

  • Ghosh PF, AK KRM (2009) Qualitative assessment of innovations in healthcare provision. BMC Health Serv Res 9:50

    Article  PubMed  Google Scholar 

  • Hiatt RA (1997) Behavioral research contributions and needs in cancer prevention and control: adherence to cancer screening advice. Prev Med 26:S11–18

    Article  PubMed  CAS  Google Scholar 

  • Holtgrave DR, Qualls NL, Graham JD (1996) Economic evaluation of HIV prevention programs. Annu Rev Public Health 17:467–488

    Article  PubMed  CAS  Google Scholar 

  • Howell A, Bundred NJ, Cuzick J, Allred DC, Clarke R (2008) Response and resistance to the endocrine prevention of breast cancer. Adv Exp Med Biol 617:201–211

    Article  PubMed  CAS  Google Scholar 

  • Kaplan RM, Porzsolt F (2008) The natural history of breast cancer. Arch Int Med 168:2302–2303

    Article  Google Scholar 

  • Li Y, Brown PH (2009) Prevention of ER-negative breast cancer. Recent Results Cancer Res 181: 121–134

    Article  PubMed  CAS  Google Scholar 

  • Mach E (1976) On thought explanatory experiments. In: Mach E (ed) Knowledge and error: sketches on the psychology of enquiry. Reidel, Dordrecht (Translation of Erkenntnis und Irrtum, 5th edn, 1926).

    Google Scholar 

  • Magai C, Consedine N, Neugut AI, Hershman DL (2007) Common psychosocial factors underlying breast cancer screening and breast cancer treatment adherence: a conceptual review and synthesis. J Womens Health 16:11–23

    Article  Google Scholar 

  • Mahoney MC, Bevers T, Linos E, Willett WC (2008) Opportunities and strategies for breast cancer prevention through risk reduction. CA Cancer J Clin 58:347–371

    Article  PubMed  Google Scholar 

  • Malavaki C, Mizumoto S, Karamanos N, Sugahara K (2008) Recent advances in the structural study of functional chondroitin sulfate and dermatan sulfate in health and disease. Connect Tissue Res 49:133–139

    Article  PubMed  CAS  Google Scholar 

  • Manau C, Cuenca E, Martínez-Carretero J, Salleras L (1987) Economic evaluation of community programs for the prevention of dental caries in Catalonia, Spain. Commun Dent Oral Epidemiol 15:297–300

    Article  CAS  Google Scholar 

  • Martín-López R, Hernández-Barrera V, Lopez De Andres A, Garrido PC, Gil De Miguel A, García RJ (2010) Breast and cervical cancer screening in Spain and predictors of adherence. Eur J Cancer Prev 19:227–238

    Article  Google Scholar 

  • Meador CK (1965) The art and science of nondisease. N Engl J Med 272:92–95

    Article  PubMed  CAS  Google Scholar 

  • Metcalfe KA (2009) Oophorectomy for breast cancer prevention in women with BRCA1 or BRCA2 mutations. Womens Health 5:63–68

    CAS  Google Scholar 

  • Misono S, Weiss NS, Fann JR, Redman M, Yueh B (2008) Incidence of suicide in persons with cancer. J Clin Oncol 26:4731–4738

    Article  PubMed  Google Scholar 

  • Osada N, Mano S, Gojobori J (2009) Quantifying dominance and deleterious effect on human disease genes. Proc Natl Acad Sci USA 106:841–846

    Article  PubMed  CAS  Google Scholar 

  • Paukov VS (2007) Structural and functional conception of alcohol disease. Zh Nevrol Psikhiatr Im S S Korsakova Suppl 1:8–11

    PubMed  CAS  Google Scholar 

  • Popper K (1968) On the use and misuse of imaginary explanatory experiments, especially in quantum theory. In: Popper K (ed) The logic of scientific discovery. Harper Torch Books, New York, pp 442–456

    Google Scholar 

  • Porzsolt F, Hölzel D (2009) Spontaneous remissions in breast cancer underline the need of more evidence: screening should not detect more cancer but earlier cancer. J Publ Health 18:15–19. doi:10.1007/s10389-009-0275-4

    Article  Google Scholar 

  • Porzsolt F, Eisemann M, Habs M (2010) Complementary alternative medicine and traditional scientific medicine should use identical rules to complete clinical trials. EUJIM 2:3–7. doi:10.1016/j.eujim.2010.02.001 http://dx.doi.org/10.1016/ j.eujim.2010.02.001

  • Powles TJ (2008) Prevention of breast cancer using SERMs. Adv Exp Med Biol 630:232–236

    Article  PubMed  CAS  Google Scholar 

  • Rockson SG (2009) Appropriate secondary prevention of acute atherothrombotic events and strategies to improve guideline adherence. Postgrad Med 121:25–39

    Article  PubMed  Google Scholar 

  • Stirratt MJ, Gordon CM (2008) Adherence to biomedical HIV prevention methods: considerations drawn from HIV treatment adherence research. Curr HIV/AIDS Rep 5:186–192

    Article  PubMed  Google Scholar 

  • Tager AM, Sondik EJ (1985) Economic evaluation of the benefits of cancer prevention and health promotion programs. Md Med J 34:77–82

    PubMed  CAS  Google Scholar 

  • Valachis A, Polyzos NP, Georgoulias V, Mavroudis D, Mauri D (2010) Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: a meta-analysis. Gynecol Oncol 117:139–145

    Article  PubMed  CAS  Google Scholar 

  • Wang LY, Yang Q, Lowry R, Wechsler H (2006) Counterpoint: uncertainty in the economic analysis of school-based obesity prevention programs: urgent need for quality evaluation. Obesity 14:1483–1484

    Article  PubMed  Google Scholar 

  • Wedzicha JA, Hurst JR (2007) Structural and functional co-conspirators in chronic obstructive pulmonary disease exacerbations. Proc Am Thorac Soc 4:602–605

    Article  PubMed  Google Scholar 

  • Welsh J (2007) Vitamin D and prevention of breast cancer. Acta Pharmacol Sin 28:1373–1382

    Article  PubMed  CAS  Google Scholar 

  • Wickerham DL, Costantino JP, Vogel VG, Cronin WM, Cecchini RS, Ford LG, Wolmark N (2009) The use of tamoxifen and raloxifene for the prevention of breast cancer. Recent Results Cancer Res 181:113–119

    Article  PubMed  CAS  Google Scholar 

  • Zahl PH, Mæhlen J, Welch HG (2008) The natural course of invasive breast cancer detected by mammography. Arch Intern Med 168:2311–2316

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Economics, University of Ulm, Frauensteige 6, 89075, Ulm, Germany

    Franz Porzsolt

Authors
  1. Franz Porzsolt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Franz Porzsolt .

Editor information

Editors and Affiliations

  1. Prävention (ZeTuP), Zentrum für Tumordiagnostik und, Rorschacherstr. 150, St. Gallen, 9006, Switzerland

    Hans-Jörg Senn

  2. Prävention (ZeTuP), Zentrum für Tumordiagnostik und, Rorschacherstr. 150, St. Gallen, 9006, Switzerland

    Florian Otto

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Berlin Heidelberg

About this chapter

Cite this chapter

Porzsolt, F. (2010). Lessons Learned from Prevention Programs: Different Endpoints Should Be Used in Secondary and Tertiary Prevention. In: Senn, HJ., Otto, F. (eds) Clinical Cancer Prevention. Recent Results in Cancer Research, vol 188. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-10858-7_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-10858-7_2

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-10856-3

  • Online ISBN: 978-3-642-10858-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation